Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

04/04/17

- Preclinical Data Presented at the AACR 2017 Meeting - BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data outlining the potential therapeutic utility
Read more

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 22.5 KB
Summary Toggle Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

04/02/17

- Preclinical Data Presented at the AACR 2017 Meeting -

Read more

Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways 23.6 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

03/28/17

Conference Call Scheduled March 28, 2017 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 41.3 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

03/21/17

BERKELEY HEIGHTS, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results 17.2 KB
Summary Toggle Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

03/07/17

CYC065 found effective against lung cancer cell lines including those with KRAS mutations

Read more

Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI 21 KB
Summary Toggle Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia

02/23/17

- Study did not reach statistically significant improvement in the primary endpoint of overall survival - - Improvement in secondary endpoint of complete remission rate for the experimental arm - - Conference call scheduled today at 9:00 AM Eastern Time - BERKELEY HEIGHTS, N.J., Feb.
Read more

Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 26.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

02/06/17

BERKELEY HEIGHTS, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference 17.7 KB
Summary Toggle Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia

12/01/16

-Preclinical Data Presented at the 28th EORTC-NCI-AACR Symposium-

Read more

Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia 23.5 KB
Summary Toggle EORTC-NCI-AACR 2016. Abstract 355: Therapeutic potential of novel PLK1 inhibitor, CYC140, in esophageal cancer and acute leukemia

12/01/16

EORTC-NCI-AACR 2016. Abstract 355: Therapeutic potential of novel PLK1 inhibitor, CYC140, in esophageal cancer and acute leukemia
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

11/14/16

Conference Call Scheduled for November 14, 2016 at 4:30 p.m. ET

Read more

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results 39.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results

11/07/16

BERKELEY HEIGHTS, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results 18.3 KB
Summary Toggle Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016

09/06/16

Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma

Read more

Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 77.4 KB
Summary Toggle Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

08/10/16

Conference Call Scheduled August 10, 2016 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results 39.2 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results

08/03/16

BERKELEY HEIGHTS, N.J., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results 17.4 KB
Summary Toggle Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers

08/02/16

- Data support CYC065 as potential treatment for chemotherapy-resistant, CCNE1-amplified, uterine serous carcinoma (USC); 90% of tumor samples overexpressed cyclin E1 (CCNE1) - BERKELEY HEIGHTS, N.J., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Read more

Cyclacel's CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers 23.3 KB
Summary Toggle Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements

06/16/16

BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements 18.4 KB
Summary Toggle Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO

06/06/16

Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations

Read more

Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO 31.2 KB
Summary Toggle Cyclacel Announces Reverse Stock Split

05/27/16

BERKELEY HEIGHTS, N.J., May 27, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Announces Reverse Stock Split 20.3 KB
Summary Toggle Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

05/19/16

BERKELEY HEIGHTS, N.J., May 19, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of
Read more

Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19.9 KB
Summary Toggle Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

05/11/16

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results 38.8 KB

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter